Consensus Blueprint Medicines Corporation

Equities

BPMC

US09627Y1091

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-24 pm EDT			5-day change	1st Jan Change
102.8 ^USD	+0.41%		-2.05%	+11.46%

May. 23	Blueprint Medicines Says BLU-222 Combination Well Tolerated for Inhibitor in Type of Breast Cancer	MT
May. 23	Blueprint Medicines Corporation to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting	CI

Evolution of the average Target Price on Blueprint Medicines Corporation

Price target over the last 5 years

History of analyst recommendation changes

7bcc2.RAENhe1vwc7xZCqMp_VhZr2JKcZ1ws43gCXrkjotDao.cVVFtI84-KLAJUK_zKw7EdPweZAwhr1253eGq0hBQf8bZ2vkgSOsv5cKTQ~d19bef9483d4f8157f67e265068c3600

Analyst Recommendations on Blueprint Medicines Corporation

Stephens Starts Blueprint Medicines With Overweight Rating, $140 Price Target	May. 14	MT
Blueprint Medicines Insider Sold Shares Worth $1,050,000, According to a Recent SEC Filing	May. 06	MT
Goldman Sachs Adjusts Price Target on Blueprint Medicines to $168 From $121, Maintains Buy Rating	May. 06	MT
Leerink Upgrades Blueprint Medicines to Market Perform, Price Target at $97	May. 06	MT
Wedbush Raises Blueprint Medicines' Price Target to $120 From $110 After Stronger-Than-Expected Q1 Results, Keeps Outperform Rating	May. 02	MT
Wedbush Adjusts Blueprint Medicines' PT to $110 From $97, Keeps Outperform Rating	Feb. 15	MT
Barclays Increases Price Target on Blueprint Medicines to $70 From $58, Maintains Equalweight Rating	Feb. 13	MT
Oppenheimer Raises Blueprint Medicines Price Target to $90 From $85, Maintains Outperform Rating	Jan. 31	MT
Stifel Adjusts Blueprint Medicines' Price Target to $97 From $95, Keeps Buy Rating	Jan. 09	MT
Wedbush Lowers Blueprint Medicines' PT to $97 From $100 After Discussion of Strategic Priorities for 2024, Pipeline Update; Keeps Outperform Rating	Jan. 08	MT
Raymond James Adjusts Blueprint Medicines' Price Target to $100 From $85, Keeps Strong Buy Rating	Dec. 22	MT
Wells Fargo Raises Blueprint Medicines Price Target to $115 From $86, Maintains Overweight Rating	Dec. 19	MT
Wedbush Raises Blueprint Medicines Price Target to $100 From $80, Maintains Outperform Rating	Dec. 11	MT
North American Morning Briefing : Rate Decisions, -2-	23-10-30	DJ
Morgan Stanley Adjusts Price Target on Blueprint Medicines to $63 From $59, Maintains Equalweight Rating	23-10-27	MT
Barclays Raises Price Target on Blueprint Medicines to $58 From $46, Maintains Equalweight Rating	23-10-27	MT
Needham Raises Blueprint Medicines Price Target to $74 From $66, Maintains Buy Rating	23-10-27	MT
Oppenheimer Upgrades Blueprint Medicines to Outperform From Perform, $85 Price Target	23-10-27	MT
Wedbush Raises Blueprint Medicines' Price Target to $80 From $75 After Higher-Than-Expected Q3 Financial Results, Keeps Outperform Rating	23-10-26	MT
Needham Adjusts Price Target on Blueprint Medicines to $66 From $65, Maintains Buy Rating	23-08-21	MT
Goldman Sachs Adjusts Price Target on Blueprint Medicines to $83 From $93, Maintains Buy Rating	23-08-03	MT
Morgan Stanley Adjusts Price Target on Blueprint Medicines to $59 From $55, Maintains Equal-Weight Rating	23-08-03	MT
Wells Fargo Upgrades Blueprint Medicines to Overweight From Equalweight, Adjusts Price Target to $82 From $55	23-07-31	MT
Wells Fargo Raises Price Target on Blueprint Medicines to $55 From $48, Maintains Equal-Weight Rating	23-06-14	MT
SVB Securities Downgrades Blueprint Medicines to Underperform From Market Perform, Cuts Price Target to $43 From $48	23-06-05	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

102.8 USD

Average target price

119.4 USD

Spread / Average Target

+16.15%

High Price Target

168 USD

Spread / Highest target

+63.41%

Low Price Target

75 USD

Spread / Lowest Target

-27.05%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Blueprint Medicines Corporation

Stephens Inc.
Goldman Sachs
Leerink Partners
Wedbush
Barclays
Oppenheimer
Stifel Nicolaus
Raymond James
Wells Fargo Securities
Needham & Co.
Morgan Stanley
SVB Securities LLC
Guggenheim
HC Wainwright
Berenberg Bank
Jefferies & Co.
Citigroup
Piper Sandler
Baird
SVB Leerink
Credit Suisse

Ratings for Blueprint Medicines Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar